新华社北京7月4日电（记者李恒）即将迎来小暑节气，我国大部分地区气温持续升高，雷雨多发， 空气湿度逐渐增加，健康问题备受关注。4日，国家卫生健康委以"时令节气与健康"为主题举行新闻发 布会，围绕三伏贴使用、腹泻治疗等话题，为公众健康过夏提供指引。 三伏贴作为中医"冬病夏治"的代表疗法，近年来广受欢迎。中国中医科学院西苑医院主任医师王凤 云介绍，三伏贴适用范围包括受凉以后就容易发作或者在冬季容易反复发作的疾病。儿童贴敷时间不宜 过长，一般以0.5小时到2小时为宜，要密切观察孩子皮肤反应情况，如果有过敏要及时停用；老年人使 用三伏贴时，若出现皮肤红肿、瘙痒等不适，应立即停用，必要时咨询医生；孕妇禁用三伏贴。 腹泻问题，夏季高发。北京协和医院主任医师李景南指出，多数情况下，腹泻的发生与肠道内环境 紊乱密切相关。补充益生菌对于改善肠道菌群、调节肠道内环境紊乱可以起到一定的辅助作用。 近年来，每逢暑假，医疗美容就迎来一波热潮。中国医学科学院整形外科医院主任医师王永前提 示，医疗美容的本质是医疗行为，要充分了解医疗美容项目的风险和实际效果。前往医疗机构、使用正 规的产品和器械，可以大大降低风险，但不建议未成年人接受医美手 ...

Corporate Presentation March 2024 Forward-Looking Statements This presentation contains statements about our future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks relating to: both our and our collaborators' ability to successfull ...

编号：20250702 投资者关 系活动类 别 □特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □√ 现场参观 □ 一对一沟通 □其他 参与单位 名称及人 员姓名 中信证券、信达证券、大成基金、国投瑞银、华安基金、 淡水泉投资等 13 人 时间 2025 年 7 月 2 日 地点 公司会议室 上市公司 接待人员 董事会办公室 投资者关 系活动主 要内容介 绍 一、参观公司展厅及臻宝博物馆； 二、问答环节： 各方还就开店情况、海外门店情况、珠宝产品系列情况、新品 规划情况、产品结构情况、电商业务等内容进行了交流，可参阅公 司已披露公告、互动平台问答和前次活动记录表之问答。 交流过程中严格按照有关制度规定，没有出现未公开重大信 息泄露等情况。 附件清单 无 | | | 证券代码：002345 证券简称：潮宏基 广东潮宏基实业股份有限公司投资者关系活动记录表 ...

Core Viewpoint - A lawsuit has been filed against Compass Diversified Holdings and its executives for potential violations of federal securities laws, stemming from material misstatements in financial statements related to its subsidiary, Lugano Holdings, Inc. [1][3][4] Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Central District of California, titled Matthews v. Compass Group Diversified Holdings, Inc., et al., No. 25-cv-981 [2] - Investors have until July 8, 2025, to request to be appointed to lead the case [2] Group 2: Financial Misstatements - Compass admitted that its fiscal 2022-2024 financial statements contained material misstatements regarding unrecorded financing arrangements and irregularities in sales, cost of sales, inventory, and accounts receivable for Lugano [3] - On May 7, 2025, Compass announced that investors should not rely on its fiscal 2024 financial statements due to an ongoing internal investigation, leading to a stock price decline of approximately 62%, from $17.25 to $6.55 per share [4] - On June 25, 2025, Compass further advised that investors should not rely on its fiscal 2022 and 2023 financial statements amid the ongoing investigation [5] Group 3: Legal Representation - Bleichmar Fonti & Auld LLP, a leading law firm in securities class actions, is representing the plaintiffs in this case [7] - The firm operates on a contingency fee basis, meaning there are no upfront costs for shareholders [6]

Core Viewpoint - A lawsuit has been filed against Elevance Health, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to the company's handling of Medicaid eligibility redeterminations and its financial disclosures [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of Indiana, captioned Miller v. Elevance Health, Inc., et al., No. 25-cv-0092 [2]. - Investors who purchased Elevance common stock are encouraged to seek additional information and may request to be appointed to lead the case by July 11, 2025 [2]. Group 2: Company Operations and Allegations - Elevance provides health insurance plans, including contracts with states to administer Medicaid benefits, which were paused during COVID but resumed in 2023 [3]. - The company claimed to be monitoring cost trends related to the Medicaid redetermination process and believed its negotiated rates were adequate for the risk profiles of Medicaid patients [4]. - Contrary to these claims, the redetermination process led to a significant increase in the acuity and utilization of Elevance's Medicaid members, which was not reflected in the company's financial guidance for 2024 [5]. Group 3: Stock Performance and Financial Impact - Following Elevance's announcement on July 17, 2024, regarding increased Medicaid utilization, the stock price fell by $32.21, or nearly 6%, from $553.14 to $520.93 per share [6]. - On October 17, 2024, Elevance reported Q3 2024 results, missing consensus EPS expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business, resulting in a stock price decline of $52.61, or nearly 11%, from $496.96 to $444.35 per share [7].

Core Viewpoint - A lawsuit has been filed against Organon & Co. and its senior executives for potential violations of federal securities laws, particularly related to misleading statements about the company's dividend policy following a significant acquisition [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of New Jersey, titled Hauser v. Organon & Co., et al., No. 25-cv-05322, and investors have until July 22, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Organon securities [2]. Group 2: Company Background and Acquisition - Organon is a global healthcare company focused on women's health, known for rewarding shareholders with dividends [3]. - In October 2024, Organon completed a $1.2 billion acquisition of Dermavant, a biopharmaceutical company, which increased its debt [3]. Group 3: Dividend Policy and Stock Performance - Following the acquisition, Organon assured investors it would maintain its dividend, claiming it was the "1 capital allocation priority," but later shifted focus to debt reduction, leading to a significant dividend cut [3]. - On May 1, 2025, Organon announced a reduction in its dividend payout from $0.28 per share to $0.02 per share, resulting in a stock price decline of approximately 27%, from $12.93 to $9.45 per share [4].

NEW YORK, July 04, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Hims & Hers, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/hims-hers-health-inc-class-action. Investors have until August 25, 2025, to ask th ...

NEW YORK, July 04, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Fortrea Holdings Inc. (NASDAQ: FTRE) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Fortrea you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/fortrea-holdings-inc-class-action-lawsuit. Investors have until August 1, 2025, to ask th ...

FINANCIAL RESULTS Q4 2024 Forward-Looking Statements This presentation contains certain forward-looking statements. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements may include statements concerning the Company's plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts, identified by words such as "believe," " ...

Corporate Presentation June 2025 JENNIFER Living with SCA3 JENNIFER Living with SCA3 Participant in the Troriluzole Clinical Study © 2025 Biohaven, Ltd. All rights reserved. Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about Biohaven Ltd. (the "Company") and our planned and ongoing trials for our troriluzole, taldefgrobep alfa, BHV-7000, BHV-2100, BHV-8000, BHV-1300, BHV-1400, ...